🎙️ On March 4, 5, and 6, 2026, the 23rd Annual Congress of the European Neuroendocrine Tumor Society (ENETS) was held in Kraków. Several relevant studies were presented at this congress, focusing on patients with neuroendocrine tumors:

DAREON-7 trial (Dr. Jaume Capdevila): obrixtamig + platinum-based chemotherapy in extrapulmonary neuroendocrine carcinoma. Response rate: 75%, median duration: 8.8 months.

Paltusotine: an oral somatostatin analogue; 74% of patients were progression-free at 1 year in carcinoid syndrome.

Cabozantinib in grade 3 NETs: PFS 8.53 months, response rate 22%.

Radionuclide retreatment (David Chan, Australia): selected patients, most (92%) with >12 months between the first cycle and retreatment with Lutathera. 35% received radiosensitizing chemotherapy. Response rate: 31%, median PFS: 17.4 months.

GETNE Registry (Vall d’Hebron University Hospital team): retrospective study comparing temozolomide-based chemotherapy vs streptozocin-based chemotherapy, showing very similar PFS.

GETNE Registry (Dr. Rosero): analysis of young patients with neuroendocrine tumors, identifying that the 40-year age cutoff is associated with differences in survival.

ENETS Theranostics / Fundación Jiménez Díaz: development of a score to measure tumor volume in neuroendocrine tumors, currently undergoing external and international validation.

An essential episode to learn about new therapeutic strategies and the personalization of treatment in NETs.

--------------------------

The purpose of this podcast is to provide continuing medical education and to inform healthcare professionals.

This content is not a substitute for professional medical care and is not intended to be used for the diagnosis or treatment of specific cases. The participants express their own opinions, experiences, and conclusions.